Key clinical point: Cotadutide vs placebo was safe and effective in reducing body weight, glycated hemoglobin (HbA1c) level, and fasting plasma glucose level in patients with type 2 diabetes mellitus (T2D) and overweight or obesity.
Major finding: Percent decrease in body weight (mean difference [MD] 3.31; 95% CI 2.76-3.38) and glucose area under the plasma concentration curve (MD 30.15; 95% CI 23.18-37.12) and reduction in HbA1c (MD 0.68; 95% CI 0.58-0.79) and fasting plasma glucose (MD 31.31 mg/dL; 95% CI 22.59-40.04) levels over time were higher with cotadutide than placebo. Treatment -emergent serious adverse events were not significantly different between the treatment groups.
Study details: Findings are from a meta-analysis of eight randomized controlled trials including 1259 patients with T2D (body mass index 22-40 kg/m 2) who received cotadutide (n = 890), placebo (n = 259), or other interventions (n = 110).
Disclosures: The study was funded by the Science, Technology & Innovation Funding Authority in cooperation with The Egyptian Knowledge Bank. The authors declared no conflicts of interest.
Source: Ali MM et al. Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis BMC Endocr Disord. 2022;22:113 (Apr 29). Doi: 10.1186/s12902-022-01031-5